All Updates

All Updates

icon
Filter
Product updates
Foundation Medicine launches FoundationOne RNA tissue-based RNA sequencing test
Precision Medicine
May 21, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
Precision Medicine

Precision Medicine

May 21, 2024

Foundation Medicine launches FoundationOne RNA tissue-based RNA sequencing test

Product updates

  • Foundation Medicine announced the launch of its FoundationOne RNA, a tissue-based RNA sequencing test. The test is claimed to be capable of detecting cancer-related fusions across 318 genes, reporting fusions present in non-small cell lung cancer, cholangiocarcinoma, sarcoma, and pancreatic, thyroid, and bladder cancer. The test was first made available in September 2023 for research and investigational use and is now being launched for clinical use.

  • The company asserts that the FoundationOneRNA can provide an additional layer of fusion detection in 318 genes, expanding its capabilities beyond its DNA sequencing test, FoundationOne CDx. The RNA test results are combined with those of FoundationOne CDx into a single report to deliver actionable fusion data to healthcare providers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.